Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Suppression of endogenous human TRAM expression decreases R848 mediated <i>CCL5</i> and <i>IFN-β</i>, but not <i>TNF-α</i> expression. by Enda Shevlin (628477)

C1INH significantly decreased renal C5a cleavage and limited C3b deposition in kidneys subjected to IRI. by Juan S. Danobeitia (4386205)

DHT increases whereas orchidectomy decreases the seminal vesicle weight in wild-type and SOD1-G93A mice. by Young-Eun Yoo (323357)

“…Conversely, orchidectomy decreased the seminal vesicle weight in both WT mice (28.4±13 mg, <i>p</i><0.0001) and SOD1 mice (20.8±3.5 mg, <i>p</i><0.0001) compared with control WT and SOD1 mice, respectively. …”

Pro- and anti-inflammatory cytokines are significantly decreased at acute time points following IR. by Jordan A. Gunning (18143970)

Mean percentage increases or decreases in developmental time for predatory larvae treated with topical sprays of four pyrethroid insecticides applied at various concentrations by J.P. Michaud (21838)